<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04318678</url>
  </required_header>
  <id_info>
    <org_study_id>CATCHAML</org_study_id>
    <nct_id>NCT04318678</nct_id>
  </id_info>
  <brief_title>CD123-Directed Autologous T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)</brief_title>
  <official_title>CD123-Directed Autologous T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Children's Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Jude Children's Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The CD123-CAR T-cell therapy is a new treatment that is being investigated for treatment of&#xD;
      AML, T-ALL, B-ALL or BPDCN. The purpose of this study is to find the maximum (highest) dose&#xD;
      of CD123-CAR T cells that is safe to give to these patients. This would include studying the&#xD;
      side effects of the chemotherapy, as well as the CD123-CAR T-cell product on the recipient's&#xD;
      body, disease and overall survival.&#xD;
&#xD;
      Primary Objective&#xD;
&#xD;
      To determine the safety of one intravenous infusion of escalating doses of autologous,&#xD;
      CD123-CAR T cells in patients (≤21 years) with recurrent/refractory CD123+ disease (AML,&#xD;
      B-ALL, T-ALL or BPDCN) after lymphodepleting chemotherapy.&#xD;
&#xD;
      Secondary Objectives&#xD;
&#xD;
      To evaluate the antileukemia activity of CD123-CAR T cells.&#xD;
&#xD;
      Exploratory Objectives&#xD;
&#xD;
        -  To assess the immunophenotype, clonal structure and endogenous repertoire of CD123-CAR T&#xD;
           cells and unmodified T cells&#xD;
&#xD;
        -  To characterize the cytokine profile in the peripheral blood and CSF after treatment&#xD;
           with CD123-CAR T cells&#xD;
&#xD;
        -  To characterize tumor cells post CD123-CAR T-cell therapy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate the safety and maximum tolerated dose of CD123-CAR T cells.&#xD;
&#xD;
      This study contains 2 phases.The first part is the called the &quot;Collection and Manufacturing&#xD;
      Phase&quot; and the second is the &quot;Treatment Phase&quot;.&#xD;
&#xD;
      The Collection and Manufacturing Phase refers to your blood cells being collected and&#xD;
      possibly frozen, via a process called apheresis. These cells will then be changed to improve&#xD;
      their ability to recognize and kill cancer cells.&#xD;
&#xD;
      The Treatment Phase refers to the portion of the study in which you receive an infusion of&#xD;
      the CD123-CAR T cells that were made in the Collection and Manufacturing Phase; chemotherapy&#xD;
      is given for several days prior to the cellular infusion. You are then monitored for any&#xD;
      possible side effects.&#xD;
&#xD;
      .&#xD;
&#xD;
      Chemotherapy is given to get your body ready to accept the CATCHAML treatment.&#xD;
&#xD;
      Treatment Schedule:&#xD;
&#xD;
      Patients will receive lymphodepleting chemotherapy followed by infusion of CD123-CAR T cells&#xD;
&#xD;
      Fludarabine on day -4, -3 and -2&#xD;
&#xD;
      Cyclophosphamide on day -3 and -2&#xD;
&#xD;
      REST DAY on day -1&#xD;
&#xD;
      CD123-CAR T cell infusion on day 0 or +1&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 27, 2020</start_date>
  <completion_date type="Anticipated">July 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of CD123-CAR T cells (CATCHAML)</measure>
    <time_frame>4 weeks after CD123-CAR T-cell infusion</time_frame>
    <description>A phase I design to determine the maximum tolerated dose (MTD) of autologous, CD123- CAR T cells. Four dose levels (3x10^5/kg, 1x10^6/kg, 3x10^6/kg, and 1x10^7/kg) will be evaluated.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>AML</condition>
  <condition>B-ALL</condition>
  <condition>T-ALL</condition>
  <condition>BPDCN</condition>
  <arm_group>
    <arm_group_label>CD123-CAR T cell therapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>CD123-CAR T-cell dose and infusion Up to 4 Dose levels will be evaluated with a maximum dose of 2.5 x 10^8 CAR+ T cells. If dose limiting toxicities (DLTs) are observed on Dose level 1 then the cell dose is de- escalated.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CD123-CAR T</intervention_name>
    <description>To treat relapsed/refractory CD123+ AML, B-ALL, T-ALL or BPDCN patient population that needs new cancer-directed therapies.</description>
    <arm_group_label>CD123-CAR T cell therapy</arm_group_label>
    <other_name>CD123-CAR T cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide is a nitrogen mustard derivative. It acts as an alkylating agent that causes cross-linking of DNA strands by binding with nucleic acids and other intracellular structures, thus interfering with the normal function of DNA.</description>
    <arm_group_label>CD123-CAR T cell therapy</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Fludarabine phosphate is a synthetic purine nucleoside analog. It acts by inhibiting DNA polymerase, ribonucleotide reductase and DNA primase by competing with the physiologic substrate, deoxyadenosine triphosphate, resulting in inhibition of DNA synthesis</description>
    <arm_group_label>CD123-CAR T cell therapy</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesna</intervention_name>
    <description>Mesna is a synthetic sulfhydryl (thiol) compound. Mesna contains free sulfhydryl groups that interact chemically with urotoxic metabolites of oxaza-phosphorine derivatives such as cyclophosphamide and ifosfamide</description>
    <arm_group_label>CD123-CAR T cell therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Rituximab is a monoclonal antibody directed against the CD20 antigen on the surface of B-lymphocytes</description>
    <arm_group_label>CD123-CAR T cell therapy</arm_group_label>
    <other_name>Rituxan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for Procurement and T-cell Production:&#xD;
&#xD;
          -  Age ≤21 years old&#xD;
&#xD;
          -  Relapsed/refractory CD123+ disease defined as follows:&#xD;
&#xD;
        AML&#xD;
&#xD;
          -  Relapsed disease: Patients developing recurrent disease after a first complete&#xD;
             remission (CR)&#xD;
&#xD;
          -  Refractory disease: Patients not achieving a CR after 2 cycles of induction&#xD;
             chemotherapy&#xD;
&#xD;
        B-cell ALL&#xD;
&#xD;
          -  Relapsed disease that is CD123 positive and CD19 negative/dim or patients otherwise&#xD;
             ineligible for CD19 directed therapies including&#xD;
&#xD;
               -  Patients in 2nd or greater relapse&#xD;
&#xD;
               -  Patients with relapse after allogeneic HSCT&#xD;
&#xD;
          -  Refractory disease that is CD123 positive and CD19 negative/dim or patients otherwise&#xD;
             ineligible for CD19 directed therapies&#xD;
&#xD;
        T-cell All • Relapsed refractory disease that is CD123 positive&#xD;
&#xD;
        BPDCN&#xD;
&#xD;
        • Relapsed/refractory disease that has failed front-line therapy&#xD;
&#xD;
          -  Estimated life expectancy of &gt;12 weeks&#xD;
&#xD;
          -  Karnofsky or Lansky (age-dependent) performance score ≥50&#xD;
&#xD;
          -  Patients with a history of prior allogeneic HCT must be clinically recovered from&#xD;
             prior HCT therapy, have no evidence of active GVHD and have not received a donor&#xD;
             lymphocyte infusion (DLI) within the 28 days prior to apheresis&#xD;
&#xD;
          -  Patient must have an identified, suitable HCT donor&#xD;
&#xD;
          -  For females of child-bearing age:&#xD;
&#xD;
          -  Not lactating with intent to breastfeed&#xD;
&#xD;
          -  Not pregnant with negative serum pregnancy test within 7 days prior to enrollment&#xD;
&#xD;
          -  Meets eligibility criteria to undergo autologous apheresis, or have previously&#xD;
             undergone autologous apheresis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known primary immunodeficiency&#xD;
&#xD;
          -  History of HIV infection&#xD;
&#xD;
          -  Severe intercurrent uncontrolled bacterial, viral or fungal infection (e.g. active&#xD;
             hepatitis B or C infection or adenovirus infection)&#xD;
&#xD;
          -  History of hypersensitivity reactions to murine protein-containing products&#xD;
&#xD;
          -  Patients with acute promyelocytic leukemia (APL, t (15;17))&#xD;
&#xD;
          -  Known contraindication to the protocol defined lymphodepleting chemotherapy regimen of&#xD;
             fludarabine/cyclophosphamide.&#xD;
&#xD;
        Inclusion Criteria for Treatment:&#xD;
&#xD;
          -  Age≤21 years old&#xD;
&#xD;
          -  Detectable disease that is CD123+ (at least MRD+ disease)&#xD;
&#xD;
          -  Estimated life expectancy of &gt;8 weeks&#xD;
&#xD;
          -  Karnofsky or Lansky (age-dependent) performance score≥50&#xD;
&#xD;
          -  Patients with a history of prior allogeneic HCT must be clinically recovered from&#xD;
             prior HCT therapy, have no evidence of active GVHD and have not received a donor&#xD;
             lymphocyte infusion (DLI) within the 28 days prior to planned infusion&#xD;
&#xD;
          -  Patient must have an identified, suitable HCT donor&#xD;
&#xD;
          -  Adequate cardiac function defined as left ventricular ejection fraction &gt;40%, or&#xD;
             shortening fraction ≥25%&#xD;
&#xD;
          -  EKG without evidence of clinically significant arrhythmia&#xD;
&#xD;
          -  Adequate renal function defined as creatinine clearance or radioisotope GFR ≥50&#xD;
             ml/min/1.73m2 (GFR ≥40 ml/min/1.73m2 if &lt; 2 years of age)&#xD;
&#xD;
          -  Adequate pulmonary function defined as forced vital capacity (FVC)≥50% of predicted&#xD;
             value; or pulse oximetry≥92% on room air if patient is unable to perform pulmonary&#xD;
             function testing&#xD;
&#xD;
          -  Total Bilirubin≤3 times the upper limit of normal for age, except in subjects with&#xD;
             Gilbert's syndrome&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤5 times the upper&#xD;
             limit of normal for age&#xD;
&#xD;
          -  Has recovered from all NCI CTAE grade III-IV, non-hematologic acute toxicities from&#xD;
             prior therapy&#xD;
&#xD;
          -  For females of child-bearing age&#xD;
&#xD;
               -  Not lactating with intent to breastfeed&#xD;
&#xD;
               -  Not pregnant with negative serum pregnancy test within 7 days prior to enrollment&#xD;
&#xD;
          -  If sexually active, agreement to use birth control until 3 months after T- cell&#xD;
             infusion. Male partners should use a condom.&#xD;
&#xD;
          -  Available autologous transduced T-cell product that has met GMP release criteria&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known primary immunodeficiency&#xD;
&#xD;
          -  History of HIV infection&#xD;
&#xD;
          -  Severe intercurrent uncontrolled bacterial, viral or fungal infection&#xD;
&#xD;
          -  History of hypersensitivity reactions to murine protein-containing products&#xD;
&#xD;
          -  History of severe hypersensitivity reactions to cornstarch or hydroxyethyl starch.&#xD;
&#xD;
          -  Receiving systemic steroids therapy exceeding the equivalent of 0.5 mg/kg/day of&#xD;
             methylprednisolone, in the 7 days prior to CD123-CAR T- cell infusion&#xD;
&#xD;
          -  Receiving systemic therapy in the 14 days prior to CD123-CAR T-cell infusion, which&#xD;
             will interfere with the activity of the CD123-CAR T cells in vivo (in the opinion of&#xD;
             the study PI(s))&#xD;
&#xD;
          -  Receiving rituximab therapy in the 30 days prior to CD123-CAR T cell infusion. (This&#xD;
             exclusion criterion is intended to prevent premature exposure of CD123-CAR Tcells to&#xD;
             rituximab, which would activate the safety switch and promote CAR T-cell apoptosis).&#xD;
&#xD;
          -  Receiving intrathecal chemotherapy in the 7 days prior to CD123-CAR T cell infusion.&#xD;
&#xD;
          -  Known contraindication to the protocol defined lymphodepleting chemotherapy regimen of&#xD;
             fludarabine/cyclophosphamide.&#xD;
&#xD;
          -  Active CNS disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paulina Velasquez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Jude Children's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paulina Velasquez, MD</last_name>
    <phone>866-178-5833</phone>
    <email>referralinfo@stjude.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>St. Jude Children's Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paulina Velasquez, MD</last_name>
      <phone>866-278-5833</phone>
      <email>referralinfo@stjude.org</email>
    </contact>
    <investigator>
      <last_name>Paulina Velasquez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.stjude.org</url>
    <description>St. Jude Children's Research Hospital</description>
  </link>
  <link>
    <url>http://www.stjude.org/protocols</url>
    <description>Clinical Trials Open at St. Jude</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 20, 2020</study_first_submitted>
  <study_first_submitted_qc>March 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2020</study_first_posted>
  <last_update_submitted>August 6, 2021</last_update_submitted>
  <last_update_submitted_qc>August 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CD123+</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant de-identified datasets containing the variables analyzed in the published article will be made available (related to the study primary or secondary objectives contained in the publication). Supporting documents such as the protocol, statistical analyses plan, and informed consent are available through the CTG website for the specific study. Data used to generate the published article will be made available at the time of article publication. Investigators who seek access to individual level de-identified data will contact the computing team in the Department of Biostatistics (ClinTrialDataRequest@stjude.org) who will respond to the data request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Data will be made available at the time of article publication.</ipd_time_frame>
    <ipd_access_criteria>Data will be provided to researchers following a formal request with the following information: full name of requestor, affiliation, data set requested, and timing of when data is needed. As an informational point, the lead statistician and study principal investigator will be informed that primary results datasets have been requested.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

